株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

C型肝炎:治療情勢に革命をもたらすための形勢を一変させる体制 - KOLの洞察

Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight

発行 FirstWord 商品コード 292629
出版日 ページ情報 英文 163 pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
C型肝炎:治療情勢に革命をもたらすための形勢を一変させる体制 - KOLの洞察 Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight
出版日: 2014年04月01日 ページ情報: 英文 163 pages
概要

当レポートでは、C型肝炎(HCV)における世界有数のKOLに対する独占インタビューをもとに、現在のHCVの治療情勢に影響を及ぼす主な要因、進歩および動向の特定と分析を行い、後期開発段階にあるパイプライン製品とそれらが将来のHCV管理をどのように修正するかに注目しており、概略以下構成でお届けします。

第1章 現在のC型肝炎市場

  • C型肝炎の概要
  • 現在の治療情勢
  • 主なC型肝炎ブランドの医療費償還
  • C型肝炎のアンメットニーズ

第2章 現在の治療法

  • 認可療法の極めて重要な治験データ
  • NS5Bヌクレオチド(Nuc)阻害剤の概要
  • NS3/NS4Aプロテアーゼ阻害剤の概要
  • インターフェロンおよびリバビリンの概要
  • ペグインターフェロンα(Peg-Intron, PegaSys)およびリバビリンの動向
  • 現在の治療アルゴリズム

第3章 将来のC型肝炎市場

  • 将来の治療情勢
  • NS5Bヌクレオチド(Nuc)阻害剤の概要
  • NS5B非ヌクレオチド阻害剤の概要
  • NS5A複製複合体阻害剤の概要
  • NS3/NS4A プロテアーゼ阻害剤の概要
  • 将来の治療アルゴリズム

第4章 C型肝炎における将来の発展

  • 認識を上げ、診断を改善するための教育
  • 将来発展する治験
  • 全ての経口療法が2014年までに認可される
  • 市場アクセスを減らす窮屈な価格環境
  • 効果的な短期療法の体制が出現
  • 最終的なバイオマーカーの開発が治療の助けとなる

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The December 2013 approval of Gilead's once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in class therapy represents a paradigm shift compared to the protease inhibitors and interferon regimens. With convenient, efficacious and safer therapies coming through the pipeline-led by Gilead, AbbVie, Bristol-Myers Squibb and Boehringer Ingelheim-the battle to transform this potentially lucrative market will be intense.

Therapy Trends: Hepatitis C is compiled from exclusive, in-depth interviews with the world's leading KOLs in HCV. It identifies and analyses the major factors, advances and trends currently influencing the HCV treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future HCV management.

FirstWord selected KOLs for this report based on their level of engagement and influence within the HCV pharmaceutical industry, and on their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how HCV clinical research will shape the future market.

Therapy Trends: Hepatitis C -- Game changing regimens to revolutionise treatment landscape examines the most prominent insights gained from the field's key opinion leaders. The results of FirstWord's research and analysis will help you to:

  • Comprehend the current trends driving and shaping the global HCV market
  • Understand the future landscape and how new classes will fit into the treatment algorithm
  • Assess the commercial and clinical potential of the pipeline nucs, non-nucs, NS5A inhibitors and next generation protease inhibitors
  • Develop planning strategies based on KOL insight
  • Identify the unmet needs and opportunities for disease management
  • Evaluate the performance of companies with the most robust new product pipelines
  • Recognise the key factors KOLs predict will drive future treatment trends

Critical Questions Answered

The hepatitis C (HCV) market is expected to become one of the fastest growing markets in Pharma over the next decade given a sizable 170 million patient population, a significant unmet need and rapid advancements in the clinic. The management of this infectious disease is on the edge of a revolution that will bring considerable changes to the treatment algorithm. KOLs from North America and Europe provide answers to some critical questions regarding the global HCV market, including:

list> What do KOLs make of the Sovaldi and Olysio and their impact on treatment? What are the current unmet needs and major challenges in HCV treatment? What are the most promising late-stage classes in development? Which therapies are KOLs eagerly awaiting? How will the nucleotide inhibitors, non-nucs, and NS5A inhibitors be positioned in the HCV market? How do the second generation protease inhibitors differ from their first-generation cousins? In what ways could eventual biomarkers improve future HCV disease management? How will treatment of HCV look in the future? How do KOLs think the pricing environment will shape the uptake of new HCV treatments? What clinical research trends do KOLs predict for future HCV therapies?

Table of Contents

1. Current Hepatitis C marketplace

  • Hepatitis C overview
  • Current treatment landscape
  • Reimbursement of key Hepatitis C brands
  • Unmet needs in Hepatitis C

2. Current therapies

  • Pivotal trial data of approved therapies
  • NS5B nucleoside (Nuc) inhibitors overview
    • Sovaldi (sofosbuvir; Gilead Sciences) trends
  • NS3/NS4A Protease inhibitor overview
    • Olysio (simeprevir; Medivir/Janssen) trends
    • Incivek/Incivo (telaprevir; Vertex's/ Janssen/Mitsubishi Tanabe) trends
    • Victrelis (boceprevir; Merck) trends
  • Interferon and Ribavirin Overview
  • Pegylated interferon-alpha (Peg-Intron, PegaSys) and ribavirin trends
  • Current treatment algorithm

3. Future Hepatitis C marketplace

  • Future treatment landscape
  • NS5B nucleoside (Nuc) inhibitors overview
    • Mericitabine (RO5024048; Roche/Gilead) trends
    • BMS-986094 (formally INX-189; Bristol Myers Squib) trends
  • NS5B non-nucleoside inhibitor overview
    • BI-201127 (Boehringer Ingelheim) trends
    • ABT-333 (AbbVie) trends
    • ABT-072 (AbbVie) trends
    • VX-222 (Vertex) trends
    • Tegobuvir (GS-9190; Gilead) trends
  • NS5A replication complex inhibitor overview
    • Daclatasvir (BMS-790052; Bristol-Myers Squibb) trends
    • GS-5885 (Gilead Sciences) trends
    • ABT-267 (AbbVie) trends
    • ACH-3102 (Achillion) trends
  • NS3/NS4A protease inhibitor overview
    • Faldaprevir (BI-201335; Boehringer Ingelheim) trends
    • ABT-450 (AbbVie/Enanta) trends
    • Asunaprevir (BMS-650032; Bristol-Myers Squibb) trends
    • Danoprevir (RO5190591; Roche) trends
    • Sovaprevir (ACH-1625; Achillion Pharmaceuticals) trends
    • Vaniprevir (MK-7009; Merck) trends
    • MK-5172 (Merck) trends
  • Future treatment algorithm

4. Future developments in Hepatitis C

  • Education to raise awareness and improve diagnosis
  • Clinical trials will evolve in the future
  • All oral regimen will be approved by 2014
  • Constrained pricing environments will reduce market access
  • Effective shorter treatment regimes will emerge
  • Eventual development of biomarkers will aid treatment
Back to Top